Teva says Q4 sales of Copaxone increased 24%

By Ted A. Knutson

Washington, Jan. 30 - Teva Pharmaceutical Industries Ltd. announced Monday that global in-market sales of Copaxone reached $323 million in the fourth quarter ended Dec. 31, an increase of 24% over the comparable quarter of 2004.

For the full year 2005, global in-market sales of Copaxone reached an all-time high of $1.176 billion, an increase of 26% over 2004.

U.S. sales in the fourth-quarter 2005 increased 26% over the fourth-quarter 2004 to $220 million. For the full year 2005, U.S. sales increased 25% to $782 million compared with the prior year.

For the fourth-quarter 2005, sales outside the United States, mainly in Europe, increased by 19% over the comparable quarter of 2004, to $103 million. For the entire year, sales outside the United States increased by 27% to $394 million.

Copaxone is an immunomodulator therapy for the treatment of relapsing- remitting multiple sclerosis.

Teva is a Petach Tikva, Israel-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.